• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

    10/22/24 4:02:34 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRUG alert in real time by email
    SC 13G/A 1 tm2426599d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    Information Statement Pursuant to Rules 13d-1 and 13d-2
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     
      Bright Minds Biosciences Inc.  
    (Name of Issuer)
     
      Common Shares, Without Par Value  
    (Title of Class of Securities)
     
      10919W405  
      (CUSIP Number)  
         
      October 15, 2024  
      (Date of Event Which Requires Filing of the Statement)  
           

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

     ¨ Rule 13d-1(b)
     x Rule 13d-1(c)
     ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 10919W405 13G Page 2 of 11 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    PFM Health Sciences, LP

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        x

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%1

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IA; PN

     

     

    1The percentages reported in this Schedule 13G are based upon 4,463,837 shares of common stock outstanding (according to the issuer’s Form 20-F as filed with the Securities and Exchange Commission on December 29, 2023).

     

     

     

     

    CUSIP No. 10919W405 13G Page 3 of 11 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    PFM Health Sciences GP, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        x

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

    CUSIP No. 10919W405 13G Page 4 of 11 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Partner Asset Management, LLC

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        x

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

    CUSIP No. 10919W405 13G Page 5 of 11 Pages

     

     

    1.

     

    NAME OF REPORTING PERSON

     

    Brian D. Grossman

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)        ¨

    (b)        x

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    U.S. Citizen

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

     

    5.

     

    SOLE VOTING POWER

    0

     

    6.

     

    SHARED VOTING POWER

    0 shares

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    See Row 6 above

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    See Row 6 above

     

    10.

     

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

     

    12.

     

     

    TYPE OF REPORTING PERSON

    IN

     

     

     

     

    CUSIP No. 10919W405 13G Page 6 of 11 Pages

     

     

    Item 1(a)Name of Issuer

    Bright Minds Biosciences Inc.

     

    Item 1(b) Address of Issuer’s Principal Executive Offices
      19 Vestry Street, New York, NY 10013

     

    Item 2(a)Name of Person Filing
    This Schedule 13G is being jointly filed by PFM Health Sciences, LP (“PFM”), PFM Health Sciences GP, LLC (“PFM-GP”), Partner Asset Management, LLC (“PAM”), and Brian D. Grossman (“Grossman” and, collectively with PFM, PFM-GP and PAM, the “Reporting Persons”) with respect to the common stock of the above-named issuer owned by PFM Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“HCM”).

     

    PFM is the investment advisor for HCM. PAM is the general partner of HCM. PFM-GP is the general partner of PFM and the manager of PAM. Grossman is the sole member of PFM-GP.

     

    The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).

     

    Item 2(b)Address or Principal Business Office or, if none, Residence
    The address of the principal business office of each of the Reporting Persons is c/o PFM Health Sciences, LP, 475 Sansome Street, Suite 1720, San Francisco, California 94111.

     

    Item 2(c)Citizenship
    PFM is organized as a limited partnership under the laws of the State of Delaware. Each of PFM-GP, HCG-GP and PAM is organized as a limited liability company under the laws of the State of Delaware. Grossman is a U.S. citizen.

     

    Item 2(d)Title of Class of Securities
    Common Shares, Without Par Value

     

    Item 2(e)CUSIP Number
    10919W405

     

     

     

     

    CUSIP No. 10919W405 13G Page 7 of 11 Pages

     

    Item 3If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under Section 15 of the Exchange Act;

     

    (b)¨ Bank as defined in Section 3(a)(6) of the Exchange Act;

     

    (c)¨ Insurance company as defined in Section 3(a)(19) of the Exchange Act;

     

    (d)¨ Investment company registered under Section 8 of the Investment Company Act;

     

    (e)¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g)¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

    (i)¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
       
      (k)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.

     

     

     

     

    CUSIP No. 10919W405 13G Page 8 of 11 Pages

     

    Item 4 Ownership

     

    A.PFM Health Sciences, LP, PFM Health Sciences GP, LLC, and Partner Asset Management, LLC

     

    (a)PFM, PFM-GP and PAM may be deemed to beneficially own 0 shares of Common Shares.

     

    (b)The number of shares PFM, PFM-GP and PAM may be deemed to beneficially own constitutes approximately 0.0% of the Common Shares outstanding.

     

      (c) Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 0

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 0

     

      B. Brian D. Grossman

     

    (a)Grossman may be deemed to beneficially own 0 shares of Common Shares.

     

    (b)The number of shares Grossman may be deemed to beneficially own constitutes approximately 0.0% of the Common Shares outstanding.

     

      (c) Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: 0

     

    (ii)shared power to vote or to direct the vote: 0

     

    (iii)sole power to dispose or to direct the disposition of: 0

     

    (iv)shared power to dispose or to direct the disposition of: 0

     

    Item 5Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    See Item 2 above

     

     

     

     

    CUSIP No. 10919W405 13G Page 9 of 11 Pages

     

    Item 8Identification and Classification of Members of the Group

    Not Applicable

     

    Item 9Notice of Dissolution of Group

    Not Applicable

     

    Item 10Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 10919W405 13G Page 10 of 11 Pages

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 22nd day of October, 2024.

     

    PFM Health Sciences, LP   PFM Health Sciences GP, LLC
             
    By: PFM Health Sciences GP, LLC,   By: /s/ Darren Mooney
    its general partner     Darren Mooney, Authorized Signatory
             
    By: /s/ Darren Mooney      
    Darren Mooney, Authorized Signatory      
           
    PARTNER Asset MANAGEMENT, LLC   BRIAN D. GROSSMAN
             
    By: PFM Health Sciences GP, LLC,   By: /s/ Darren Mooney
    its manager     Darren Mooney, attorney-in-fact*
             
    By: /s/ Darren Mooney      
    Darren Mooney, Authorized Signatory      

     

     

    * Darren Mooney is signing on behalf of Brian Grossman as attorney-in-fact pursuant to a power of attorney dated February 1, 2024, and incorporated by reference herein. The power of attorney was filed as an attachment to a filing by certain of the Reporting Persons on Schedule 13G/A for Praxis Precision Medicines, Inc. on February 14, 2024.

     

     

     

    Get the next $DRUG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRUG

    DatePrice TargetRatingAnalyst
    5/13/2025Buy
    TD Cowen
    5/7/2025$80.00Buy
    Chardan Capital Markets
    1/23/2025$93.00Overweight
    Piper Sandler
    1/10/2025Overweight
    Cantor Fitzgerald
    1/10/2025$85.00Buy
    H.C. Wainwright
    11/26/2024$75.00Outperform
    Robert W. Baird
    More analyst ratings

    $DRUG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bright Minds Biosciences Inc.

      SC 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/12/24 4:15:24 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bright Minds Biosciences Inc.

      SC 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/6/24 4:06:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Bright Minds Biosciences Inc.

      SC 13D/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      11/5/24 3:25:38 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    SEC Filings

    See more
    • SEC Form 6-K filed by Bright Minds Biosciences Inc.

      6-K - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Filer)

      4/28/25 7:05:39 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/8/25 3:14:41 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.

      SCHEDULE 13G/A - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Subject)

      4/7/25 4:07:58 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

      - BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight BMB-101's potential to address critical gaps in SUDEP prevention - NEW YORK and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced positive findings from its DBA/2 mouse model study. BMB-101, the Compan

      5/13/25 8:30:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

      VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET. The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders (KOLs) in epilepsy research, as well as an overview of the Company'

      4/28/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

      – Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company's clinical focus on epilepsy – VANCOUVER, British Columbia, March 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced the expansion of its Scientific Advisory Board (SAB) to include five distinguished experts in epi

      3/4/25 8:00:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      11/6/24 4:20:48 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

      4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:11:29 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Cormorant Asset Management, Lp claimed ownership of 452,409 shares (SEC Form 3)

      3 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

      10/17/24 5:07:59 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Financials

    Live finance-specific insights

    See more
    • Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders

      -- Review of Phase I ready BMB-101 and upcoming milestones -- -- Conference call to be held on May 19, 2022, 10:00am ET -- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape.

      4/19/22 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRUG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DRUG
    Leadership Updates

    Live Leadership Updates

    See more
    • TD Cowen initiated coverage on Bright Minds Biosciences

      TD Cowen initiated coverage of Bright Minds Biosciences with a rating of Buy

      5/13/25 9:38:46 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital Markets initiated coverage on Bright Minds Biosciences with a new price target

      Chardan Capital Markets initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $80.00

      5/7/25 8:37:12 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bright Minds Biosciences with a new price target

      Piper Sandler initiated coverage of Bright Minds Biosciences with a rating of Overweight and set a new price target of $93.00

      1/23/25 7:40:15 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

      -- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Stephen D. Collins, M.D., Ph.D., will join the Company as Chief Medical Officer (CMO), effective immediately. The Company also announces that Mark A. Smith M.D., Ph.D., will retire from his role as Acting CMO, but will continue to serve in an

      1/7/25 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

      -- First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia -- -- Company has transitioned from a discovery to a development organization – -- Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 -- VANCOUVER, British Columbia, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for a

      2/27/23 6:50:00 AM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Minds Biosciences Announces Resignation of Board Member

      VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (NASDAQ:DRUG) (CSE:DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board. "In his short tenure on the Board, Doug's scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging br

      1/9/23 4:05:00 PM ET
      $DRUG
      Biotechnology: Pharmaceutical Preparations
      Health Care